| Trial ID # | NCT03029598 |
| Phase | I/II |
| Drug Class | Immunotherapy: Checkpoint Inhibitors/PD-1 |
| Drug Name | Pembrolizumab |
| Alternate Drug Names | Keytruda, Lambrolizumab, SCH 900475, MK3475, MK-3475 |
| Drugs in Trial | Carboplatin, Pembrolizumab |
| Eligible Participant | Platinum resistant ovarian cancer |
| Patients Enrolled | 27; median 5 prior therapies (2-9) |
| Therapy Setting | Recurrence |
| Study Design | Open-Label, Non-randomized |
| Endpoints | ORR, DCR, PFS, OS, evaluated per RECIST |
| Biomarkers | Exploratory: PD-L1 status |
| Efficacy | ORR: 10.6% (3PR, n=29) 7 of 23 evaluable patients (30.4%) had archival tumor with modified percent scoring ≥5 for PD-L1 and all achieved PR (3/7, 42.8%) or SD (4/7, 57.2%) |
| Clinically Significant Adverse Events | Serious AE: |
| Conclusion | Promising activity of pembrolizumab with low dose carboplatin in heavily pretreated patients |
| Reference | Liao JB et al. Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates. J Immunother Cancer (2021) 9(9):e003122 |
Starting
January 1, 2025,
Clearity is joining
Ovarian Cancer
Research Alliance
(OCRA) and this website
will be redirected to
www.ocrahope.org
OCRA and Clearity are committed to serving the ovarian cancer community and providing the education, information, and support people need.